A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD)
Read time: 1 mins
Last updated:26th Apr 2011
To demonstrate that transdermal nicotine treatment retards disease progression as measured by change in total (part I, II, III) UPDRS score between baseline and after 52 weeks of study treatment plus two more months wash out (60 weeks).
|Study start date||2011-04-26|